What This Top Dividend Portfolio Is Holding Now: GlaxoSmithKline plc, Inmarsat Plc And UBM Plc

GlaxoSmithKline plc (LON:GSK), Inmarsat Plc (LON:ISAT) and UBM Plc (LON:UBM) are among the top holdings of Merchants Trust plc (LON:MRCH).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Merchants Trust (LSE: MRCH) has delivered 32 consecutive years of dividend increases, and carries a trailing yield of 5.1% at a current share price of 463p.

Picking great dividend shares has helped Merchants outperform the FTSE All-Share Index over the past three, five and 10 years.

The trust holds many high-yield ‘usual suspects’, including Royal Dutch Shell, HSBC and current heavyweight top-yielder GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US).

But Merchants also has a couple of interesting mid-caps within its top 10 holdings: namely, mobile satellite communications firm Inmarsat (LSE: ISAT) and media group UBM (LSE: UBM).

GlaxoSmithKline

GSK has said shareholders can expect a total dividend of 80p for 2014, and the same payout for 2015 — giving a juicy annual yield of 5.7% at a current share price of 1,410p.

Some analysts have questioned whether GSK can afford to maintain the dividend during a phase of weaker sales, but chief executive Andrew Witty said recently: “I don’t think people should be concerned about that”.

In addition to the 80p dividend, shareholders can expect a £4bn capital return (82p a share) during 2015. The payment will be funded from net cash the company will receive as a result of a deal with Swiss group Novartis (expected to complete in the first half of the year) to swap some assets and create a consumer healthcare joint venture.

Inmarsat

Inmarsat was set up in 1979 by the International Maritime Organization to enable ships to stay in constant touch with shore or to call for help in an emergency. The company was floated on the stock market in 2005, and its operations now extend across air, land and sea.

At a current share price of 809p, Inmarsat has a market value of £3.5bn and sits just outside the FTSE 100. Annual dividend growth is running at 5% and analyst forecasts for 2015 give an above-market-average yield of 4%.

Earnings forecasts don’t fully cover the projected dividend (around $40m short), but at the last reckoning Inmarsat had cash on the balance sheet of $138m and available but undrawn borrowing facilities of $891m. Furthermore, management is “very confident of the medium-term growth opportunities for the company”.

UBM

Media group UBM operates internationally in three main business segments: Events, Marketing Services and PR Newswire. The company has a market value of £2.1bn at a current share price of 473p, and offers a 4.8% yield based on 2015 dividend forecasts.

During 2014, with the aid of a rights issue, UBM made a substantial acquisition in the shape of US trade show firm Advanstar. The deal makes UBM the biggest events organiser in America. Management says it also has “the opportunity to establish UBM firmly as the leading B2B events business globally”.

At the same time, the Board committed to continuing its progressive dividend policy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline and UBM. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Here’s how I’d aim for a ton of passive income from £20k in an ISA

To get the best passive income from an ISA, I think we need to balance risk with the potential rewards.…

Read more »

Abstract bull climbing indicators on stock chart
Investing Articles

2 FTSE 100 stocks I’d buy as the blue-chip index hits record highs

This Fool takes a look at a pair of quality FTSE 100 stocks that appear well-positioned for future gains, despite…

Read more »

Satellite on planet background
Small-Cap Shares

Here’s why AIM stock Filtronic is up 44% today

The share price of AIM stock Filtronic has surged on the back of some big news in relation to its…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

At a record high, there can still be bargain FTSE 100 shares to buy!

The FTSE 100 closed at a new all-time high this week. Our writer explains why there might still be bargain…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

After profits plunge 28%, should investors consider buying Lloyds shares?

Lloyds has seen its shares wobble following the release of its latest results. But is this a chance for investors…

Read more »

Abstract bull climbing indicators on stock chart
Investing Articles

Something’s changed in a good way for Reckitt in Q1, and the share price may be about to take off

With the Reckitt share price near 4,475p, is this a no-brainer stock? This long-time Fool takes a closer look at…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

This new boost in assets might just get the abrdn share price moving again

The abrdn share price has lost half its value in the past five years. But with investor confidence returning, are…

Read more »

Young Black man sat in front of laptop while wearing headphones
Investing Articles

As revenues rise 8%, is the Croda International share price set to bounce back?

The latest update from Croda International indicates that sales are starting to recover from the end of 2023, so is…

Read more »